Patency of the fetal ductus arteriosus (DA) is maintained in an environment of low relative oxygen tension and a preponderance of vasodilating forces. In addition to prostaglandins, nitric oxide (NO), a potent vasodilator in the pulmonary and systemic vasculatures, has been implicated in regulation of the fetal DA. To further define the contribution of NO to DA patency, the expression and function of NO synthase (NOS) isoforms was examined in the mouse DA on days 17-19 of pregnancy and after birth. Our results show that endothelial NOS (eNOS) is the predominant isoform expressed in the mouse DA and is localized in the DA endothelium by in situ hybridization. Despite rapid constriction of the DA after birth, eNOS expression levels were unchanged throughout the fetal and postnatal period.
Introduction
The ductus arteriosus (DA) is a fetal vascular shunt that is interposed between the pulmonary artery and aorta. In utero, the DA conducts over 90% of right ventricular output to the aorta, bypassing the fetal pulmonary system. After birth, the transition from fetal to neonatal life is dependent on the newborn's ability to establish its own respiratory gas exchange and redirect blood flow into the vessels of the newly inflated lungs. To accomplish this, simultaneous relaxation of the pulmonary vascular bed and constriction of the DA must occur soon after delivery. Many factors have been identified that affect fetal DA patency and postnatal closure (7, 47) but the molecular sequence of events that regulate this transition have not been fully resolved.
The preterm DA is morphologically and biochemically immature (4, 46, 49) and poorly responsive to contractile stimuli compared to the full term DA (11, 30, 31, 52) . In contrast to the adjacent elastic great vessels, the DA has overlapping layers of vascular smooth muscle that facilitate rapid constriction of the DA lumen after birth. Relaxation of DA smooth muscle in utero occurs in an environment of low oxygen tension and the presence of vasodilators such as adenosine and certain prostaglandins (47) . Nitric oxide (NO) is another mediator of vascular smooth muscle tone that is implicated in regulation of the DA (10) . NO is a potent metabolite of L-arginine produced by the three known isoforms of NO synthase (NOS): type 1(neuronal or nNOS), type 2 (inducible or iNOS) and type 3 (endothelial or eNOS). Accordingly, NO is primarily found in neurons, monocytes/macrophages and vascular endothelia but is also active in the parenchyma of many other tissues. Compounds that inhibit NO synthesis constrict the lamb DA in vitro (9, 10, 13) , providing indirect evidence of endogenous NO production. NOS inhibitors also constrict the DA of other species (3, 6, 32, 43) while NO donors can dilate the DA in vitro and in vivo (6, 9, 48, 53) . Removal of the DA endothelium does not eliminate DA constriction in response to NOS inhibitors (3, 9, 10) and eNOS has been localized in the vasa vasorum of the DA (9, 20) . Both findings suggest that intramural sources of NO contribute to DA regulation. There is also recent evidence that NO mediates vasomotor tone of the immature DA more than the term DA (32, 51) , whereas prostaglandins are more important for regulation of the term DA. Combined inhibition of both NO and prostaglandin synthesis has more impact on DA patency than inhibition of either system alone (32, 43, 50) .
Currently, there is little information available to explain the differential sensitivity of the term and preterm DA to NO or prostaglandins. Controversy also exists regarding the source of NO since NO production in the lamb DA has been attributed to each of the three NOS isoforms (9, 27, 40) . The newborn mouse DA is functionally closed by 3-4 hours of age and has structural features similar to larger species (49) . Genetic and pharmacologic studies have also demonstrated the importance of mouse models of DA regulation (24, 34, 41, 42) . A recent study shows that eNOS is expressed in the mouse DA at term gestation (2) but there is no information on NO actions in the DA during development. In addition, the levels of NOS expression in a given tissue may not correlate well with the levels of NO production. We hypothesized that NO would mediate DA relaxation in utero and that declining NO synthesis would accompany DA constriction after birth. Our results show that eNOS is the predominant NOS isoform in the mouse DA. In the preterm fetal DA, we observed that NO is the primary mediator of DA tone, and is augmented by the action of prostaglandins. Conversely, prostaglandins are the primary mediator of the term fetal DA, but the contribution of NO appears less significant at this time.
Persistent expression of eNOS after DA closure suggests that NO may have additional roles in the DA remodeling process. Although the vasa vasorum are important for closure of the DA in some species, our data show that DA constriction can occur in the absence of vasa vasorum.
These findings highlight the diverse functions of NO signaling in fetal vasculature during development and provide additional insight into the mechanisms of DA regulation during vascular transition at birth.
Materials and Methods

Animals and tissues
All animals were housed in an AAALAC approved facility and were managed in accordance with NIH animal care standards. Adult female CD-1 mice Tissue specimens were collected from pups after pregnant females received deep anesthesia by isoflurane inhalation (Baxter, Deerfield, IL) and were killed by cervical dislocation at 0900h on days 17-19 of pregnancy (mice in this colony typically deliver on the evening of day 19). Fetal DAs were isolated by sharp dissection immediately after delivery from non-breathing pups that were anesthetized by maternal isoflurane. Only the first 4-6 pups were used from each litter. Newborn DA samples were removed from isoflurane-anesthetized pups at 12-18 hours of age on postpartum day 1 (PP1 Anesthetized, non-breathing fetal pups were removed for immediate assessment of DA status.
Fetuses that attempted breathing or had any evidence of lung insufflation at the time of dissection were excluded from evaluation. Fetal DAs were individually inspected as soon as they were delivered from the uterus. DA constriction was estimated by visual observation of its luminal diameter, since intimal cushion formation is not required for mouse DA closure (49) .
The degree of constriction was scored by direct visualization in 25% increments under a dissecting stereomicroscope by a single observer who was blind to the treatment group (J.R.).
The narrowest point of the DA luminal diameter was assessed in relationship to the internal caliber of the main pulmonary artery below the outlet of the branch pulmonary vessels, as previously described (41) .
Measurement of NO products
The effect of maternal L-NAME administration on fetal NO synthesis was determined in a separate group of mice from the above experiments. To examine the baseline fetal response, day 19 pregnant females were injected with a single dose of L-NAME, 50 mg/kg i.p., or 0.1 ml of saline at 0900 h. Blood samples were obtained from each pup immediately after cesarean section at 1300 h. To examine the LPS-stimulated fetal response, day 19 pregnant females received 100 mg of E.coli LPS (Sigma-Aldrich, St. Louis, MO), i.p., at 0900 h, followed by a single dose of L-NAME 50 mg/kg i.p., or 0.1 ml of saline at 1100 h. Pups were delivered by cesarean section at 1500 h, such that dams had 6 hours of LPS exposure and 4 hours of L-NAME or saline treatment prior to delivery. For both approaches, blood samples were collected in heparinized capillary tubes after cervical transection, separated by brief centrifugation, and the plasma fraction stored at -80 C for later analysis. Four to eight pups were analyzed per litter.
NO products were measured in plasma after reduction to NO using a vanadium HCl catalyst.
The NO generated was reacted in an ozone chamber and detected by chemiluminescence in a nitric oxide analyzer (Sievers 280i NOA, Boulder, CO). Sample quantification was performed by interpolation from standard curves generated from sodium nitrite injections.
Gene expression
Temporal changes in NOS isoform expression were analyzed by RT-PCR. Total RNA from day 17, 18, and 19, and PP1 DA specimens was reverse transcribed with oligo-dT and amplified with 28-30 cycles of PCR using isoform-specific primers for nNOS, iNOS, eNOS 
In situ hybridization
To examine the cell-specific localization of NOS gene expression, in situ hybridization was performed as previously described (41 
LacZ staining
Expression of the b-galactosidase reporter gene was assessed by staining for lacZ activity in day 19 and PP1 DA of wildtype or flk-1 lacZ/+ littermates. Briefly, 10 mm frozen serial sections through the heart and outflow tracts of wildtype and transgenic pups were mounted on the same glass slide, fixed in 0.2% paraformaldehyde for 10 minutes, rinsed, stained with X-gal at 37 C for 2 hours and cleared with xylene per established protocol (28) . Sections were counterstained with eosin.
Vascular casting
The vascular network surrounding the DA was examined by corrosion casts of day 19 fetuses and 1 and 3 hour old newborn pups. Fetal pups were surgically removed from anesthetized females at noon on day 19. Newborn pups were delivered by cesarean section on the afternoon of day 19 and maintained in room air until sacrifice under anesthesia. The chest wall was removed and 0. Analyses were performed using SAS version 8.2 (SAS Institute, Cary, NC).
Results
eNOS is the predominant NOS isoform expressed in the mouse ductus arteriosus
nNOS and iNOS expression were at the lower limits of detection by semi-quantitative RT-PCR. After 30 cycles of PCR, amplification products were only visible after Southern hybridization and 20-24 hour exposure times (Fig. 1A) . The use of 40 amplification cycles showed only a marginal increase in detection (data not shown). In contrast, eNOS and rpL7 expression were detected after 28 cycles and brief exposure of the Southern blots. Densitometry revealed a trend toward increased expression from day 17 to day 19 but did not reach statistical significance (p=0.22). Real-time PCR showed linear amplification of DA samples during 28-32 cycles of PCR. Quantitative analysis showed consistent, low levels of eNOS expression from day 17 through the postpartum period (Fig 1B) . There was no statistically significant difference between time points (p=0.14, d19 vs. PP1). Thus, despite the increased mass of DA tissue on PP1 after DA constriction, analysis of eNOS expression relative to the housekeeping gene rpL7
suggests that the thin and patent fetal DA has equivalent levels of eNOS expression to the thick, closed DA on PP1.
eNOS mRNA is expressed in the ductal endothelium during fetal patency and postnatal closure
The cell-specific expression pattern of eNOS was examined by in situ hybridization. On day 19, sparse eNOS autoradiographic signals were detected in the DA as well as the aorta and pulmonary artery. The compact nature of these vessels prevented distinction between signal localization in the vessel wall and endothelial surface (Fig. 2 ). Signals were increased over background but the accumulation was only somewhat higher than sense-labeled control slides.
After constriction of the DA on PP1, eNOS signals were primarily restricted to the endothelial cells in the closed DA lumen (Fig. 2) . Lower levels of eNOS signal were noted in the DA wall or adventitia, but it was unclear whether this was localized to any particular structure. Specific, low level hybridization was also observed in the endothelial surface of the aorta and main pulmonary artery and throughout the myocardium.
Developmental maturity confers differential sensitivity to NOS inhibition vs. prostaglandin inhibition
Ductal patency was estimated by direct observation of DA caliber in comparison to the main pulmonary artery. Fetuses were immobile and not breathing at birth due to maternal anesthesia, thus cervical transection and exsanguination were avoided as a cause of inadvertent fetal DA constriction. The fetuses of saline-treated females on day 16 (n = 54, 4 litters) had some reduction of DA caliber using this approach, suggesting that mild DA constriction can occur with this technique. However, the DA of day 16 pups exposed to 2 doses of indomethacin (n = 39, 3 litters), a non-selective cyclooxygenase inhibitor, was no different than saline treated pups (Fig. 3) . In contrast, day 16 fetuses that were exposed to L-NAME (n = 75, 7 litters), a non-specific inhibitor of all NOS isoforms, had more ductal constriction than either saline or indomethacin-treated mice (c 2 = 17.4; p<0.01), suggesting that NOS inhibition has more impact than cyclooxygenase inhibition at this stage of gestation. Combined treatment with two doses of L-NAME and indomethacin resulted in fetal death and increased maternal mortality (6 litters).
However, when a single dose of each inhibitor was given and c-section was performed four hours later (n = 41, 4 litters), day 16 fetuses were noted with significantly more constriction than was noted with L-NAME treatment alone (c 2 =39.7; p,0.01) (Fig. 3) .
On day 19, there was marked reduction in the DA caliber of fetuses exposed to indomethacin (n = 33, 3 litters) versus either saline (n = 50, 4 litters) or L-NAME (n = 35, 3 litters) (p<0.0001). In the majority of these cases, the DA was completely closed (Fig. 3) . DA constriction appeared somewhat more frequently in the aortic junction of the DA than the pulmonary. Pups with complete in utero DA closure were no different in external appearance than littermates with patent DAs. Despite severe DA constriction, all indomethacin-exposed fetuses were observed with regular heartbeats at the time of dissection. There was no difference in the number of fetal resorption sites between indomethacin and saline-treated females. In contrast to indomethacin treatment, there was no difference in DA caliber between L-NAME and saline-exposed fetuses on day 19. Compared to day 19 indomethacin treatment alone, combined administration of a single L-NAME and indomethacin dose did not result in further constriction of the day 19 fetal DA (p=0.12) (Fig. 3) . The effect of maternal L-NAME on fetal NO production was measured in d19 fetuses (Table 1 ). There was no difference detected in fetal NO levels between saline and L-NAME treated dams. However, others have shown that L-arginine analogs such as L-NAME may be detected by NO assays that utilize ozone chemiluminescence or the modified Griess reaction (17) . As an alternative approach, we measured NO production in the fetuses of LPS-stimulated dams. Compared to saline-treated females, NO levels were significantly reduced in the fetuses of L-NAME-treated females after LPS stimulation (Table 1) .
Taken together, these results suggest that maternally administered L-NAME inhibits fetal NO production but does not affect fetal DA patency on day 19.
Comparison of drug effects between day 16 and day 19 groups revealed that there was no difference in the degree of DA patency for saline-exposed fetuses on these days. However, a small but significant reduction in DA caliber was noted in L-NAME exposed fetuses on day 16 compared to day 19 (c 2 = 24.3; p<0.001). In contrast, indomethacin treatment had little or no effect on the day 16 DA, but caused marked constriction in the day 19 fetuses (p<0.001).
Overall, these results suggest that the preterm fetal DA is more sensitive to NOS inhibition than cyclooxygenase inhibition, although the magnitude of DA constriction by L-NAME is small.
This response is reversed in the term fetus, when the DA undergoes severe constriction in response to maternal indomethacin. Studies with combined inhibitors also suggest that NO actions are potentiated by prostaglandins in the day 16 DA. Conversely, combined inhibition of NOS and cyclooxygenase did not result in further DA constriction on day 19, possibly because the DA may already be maximally constricted.
Ductal closure in the mouse occurs in the absence of vasa vasorum
The vasa vasorum of the DA wall plays an important role in DA closure in baboons and sheep (9, 20, 43) . Corrosion casts of the fetal and newborn mouse did not reveal the presence of vasa vasorum in the media of the patent or closing mouse DA, although the extensive vascular network within the fetal lung was easily demonstrated (Fig. 4A ). In addition, immunostaining of We hypothesized that NO would mediate DA relaxation in utero and that declining NO synthesis would accompany DA constriction at birth. However, our findings show that NO contributes to regulation of DA patency in the premature more than the term fetal mouse, despite persistent eNOS expression, even in the constricted, postnatal DA.
The relaxed state of the fetal DA was historically considered a passive process, but it is clear that vasodilating stimuli are required to keep the DA open in utero (47) . NO contributes to fetal DA relaxation in baboons, sheep, rabbits and rats (6, 10, 13, 43) , but its enzymatic source is not entirely clear. We observed uniform eNOS expression in the DA of mid-to late gestation fetal mice. nNOS mRNA was barely observed and iNOS expression was noted at the lower limits of detection and is unlikely to exert a physiologic contribution at these levels. Baragatti et.
al., also detected eNOS but not nNOS or iNOS expression in the term mouse DA (2) but there was no information on temporal or cell-specific expression patterns during development. The specificity of NO synthesis may be important, since strategies to manipulate DA patency could depend on inhibition of a single isoform. Contrary to our results, Bustamante et. al., reported that the heart and conotruncal vessels of the fetal rat express iNOS mRNA and showed that the fetal DA was constricted by maternal treatment with a selective iNOS inhibitor (6) . Although the rat DA also constricts in response to non-specific NOS inhibition by L-NAME (32, 51) , the presence and localization of specific NOS isoforms has not been determined in this species. The DA of fetal sheep constricts in response to NOS inhibition (9, 10, 13), but there is uncertainty about the role of each NOS isoform. Fox et al., demonstrated immunoreactive eNOS in the lamb DA endothelium (13). However, the lack of an eNOS-selective inhibitor prevents direct evaluation of eNOS effects on DA tone. In a related series of studies, western blot and selective inhibitors also demonstrated the expression and functional contribution of nNOS in late gestation fetal lambs (40) . In those experiments, administration of an nNOS-specific inhibitor to chronically catheterized lambs in utero induced a modest increase in pulmonary-aortic arterial pressure gradients, whereas similar experiments with selective iNOS inhibition did not affect transductal pressures or flow (39) . In that study, there was no difference in the nNOS protein content of intact versus endothelium-denuded DA homogenates, suggesting nNOS localization in the muscular wall or adventitia. In vitro studies of cultured lamb DA smooth muscle cells also established nNOS as the predominant source of ductal NO, although eNOS and iNOS were detected by western blot (27). These results are in contrast to other studies showing that the fetal lamb DA expresses mRNA and protein for eNOS and iNOS but not nNOS (9) . The discrepancy over iNOS in the sheep DA may be related to localization techniques versus functional or in vitro studies. However, the controversy over nNOS is more difficult to reconcile. It is possible that the development of selective inhibitors for each isoform and application to both cultured cells and in vivo models will clarify their distinct contributions to DA tone. It is also known that eNOS regulates the baboon DA (20, 43) and there is some evidence to suggest that the human DA is influenced by NO (29) and expresses eNOS in the term and preterm endothelium (21) but a role for other isoforms has not been explored. Despite our results and the findings of other investigators, it is also possible that NOS expression levels do not correlate well with the actual production of NO in the DA. Thus, defining NOS isoform specificity in ductal tissues and developing methods to measure NO levels at the site of action remain important goals for the development of potential therapeutic interventions for the DA.
We observed differential responsiveness of the DA to NOS inhibition in preterm versus term fetal mice. There are previous reports that the preterm DA of rats and sheep are more sensitive to NOS inhibition than the term DA (20, 32, 51) but the mechanism of increased NO sensitivity is unknown. To address this, we speculated that the preterm DA might contain increased levels of NOS isoforms to actively maintain preterm DA patency and that NOS expression would decline as the time for rapid DA closure after birth approached. Instead, our observation that NOS expression is stable throughout late gestation and after birth suggests that regulation of preterm DA tone by NO may be overcome by other forces with advancing gestation. Prostaglandins are known to complement the role of NO in preserving fetal DA patency and combined inhibition has been shown to be more potent than inhibition of either system alone (32, 43, 50) . Thus, one explanation for our results is that NO remains an active dilator of the term fetal DA, but it's impact is minimal compared to prostaglandins and other vasodilators that take on a greater role near the time of delivery. Alternatively, our results are consistent with the possibility that NOS inhibition leads to a compensatory increase in dilatory prostaglandins in the preterm more than the term fetal DA. Although the term fetal DA is fully constricted by prostaglandin inhibition, constriction of the day 16 DA by combined inhibitors is greater than the response to either inhibitor alone, suggesting that synergistic effects exist between these mediators and are important for regulation of the preterm DA. Withdrawal of dilatory prostaglandin stimuli at birth is a common physiologic mechanism for DA constriction across species (47) . Pharmacologic inhibition of prostaglandin synthesis is a potent inducer of DA constriction that is more pronounced in the term than the preterm DA (30, 31, 52 ). In addition, we previously found that constriction of the mouse DA was less severe with selective cyclooxygenase-2 inhibition than with indomethacin at term (41), but this is the first report we are aware of on the differential effects of cyclooxygenase inhibition in term versus preterm mice.
Overall, our results concur with observations that prostaglandin signaling becomes increasingly important for active relaxation of the DA as the time for delivery nears. On the other hand, our data extends the concept that NO, or NO in combination with prostaglandins, contributes to relaxation of the preterm more than the term DA despite stable eNOS expression over time.
The implication of sustained eNOS mRNA expression in the constricted DA is unclear.
eNOS protein also persists in the luminal endothelium of constricted DAs in sheep and baboons (8, 20, 43) . eNOS levels are regulated by physical stimuli, numerous transcription factors and mRNA stability. It is possible that altered shear forces during DA closure influence the expression or post-transcriptional modification of eNOS after birth. However, the DA lumen is closed by 3-4 hours of age in mice and it is unlikely that increasing vascular resistance across the constricting DA is the cause of continued eNOS gene expression 12-24 hours after it is closed.
Alternatively, vascular endothelial growth factor (VEGF), endothelin (ET-1), bradykinin, calcium influx, and potassium channels are associated with various aspects of DA constriction (47) but are also key regulators of eNOS transcription or function (12, 14, 45, 55) . Persistent eNOS expression in the constricted DA may therefore be secondary to the role these factors play in DA closure and vascular remodeling. eNOS itself may also be important for DA remodeling, since NO protects against oxidant injury, inhibits leukocyte and platelet adhesion, and can inhibit proliferation of smooth muscle cells and stimulate endothelial cell migration (1, 15, 33, 35, 56) .
Unfortunately, there is no DA-specific information on calcium/calmodulin interaction, estrogen/ERs, cytokines, HSP90, caveolin, or other intracellular signaling processes that regulate eNOS activity. NO exerts its actions in the cell occur through post-translational modification of other proteins or alterations in their expression, including growth factors, cytokines, inflammatory/anti-inflammatory mediators, adhesion molecules and matrix proteins (5, 38) . In the sheep DA, NO acts on microtubule-associated proteins to induce fibronectin synthesis (27) which is critical for DA smooth muscle migration and obliteration of the DA lumen after birth (26). Thus, it is likely that eNOS has roles other than vasorelaxation in the postnatal DA.
Further studies are necessary to determine whether persistent eNOS expression in the constricted DA is functionally active and whether these expression levels correspond to sustained production of NO in the DA wall.
We also found that DA closure in the mouse occurs without contribution of the vasa vasorum. Reports that vasa vasorum facilitate DA closure in other species prompted our interest in the mouse. Numerous studies have shown that vasa vasorum are not required for nourishment of the aorta or elastic vessels in smaller species with limited wall thickness (54) . However, the DA is a muscular vessel with unique architecture and there is little information about vasa vasorum in the DA of smaller species. Our inability to demonstrate these vessels in the DA wall by fine vascular casting or with two established markers of vascular endothelium is not unexpected but raises the possibility that vasa vasorum in the tunica media may not be essential for DA regulation. These findings are important since NO activity has been observed in the wall of denuded DA segments (3, 9, 10) and eNOS localizes to the vasa vasorum of sheep, baboons and humans (9, 20, 21) . In these species, vasa vasorum are more prevalent in the term than preterm DA wall and increase with the onset of DA closure (9, 21, 43) . It is unclear whether our results merely reflect variation between large and small species or if common mechanisms for DA closure exist despite the observed changes in vasa vasorum of larger vessels. For example, prostaglandin inhibitors typically have an acute constrictive effect on the DA in utero, but prenatal exposure to indomethacin can also unexpectedly result in persistent DA patency after birth (18, 36) . In this circumstance, there is evidence that indomethacin treatment causes impaired wall perfusion and compensatory changes in the vasa vasorum, leading to postnatal DA insensitivity and increased DA patency in newborns (8, 16 ). However, prolonged in utero exposure to prostaglandin inhibitors also results in persistent DA patency in the newborn mouse (23) , where the absence of vasa vasorum implies that this event must be mediated by another process. Persistent DA patency is also noted in knockout mice that lack prostaglandin synthesis or the EP 4 prostaglandin receptor (24, 34, 41, 42) , suggesting that there are alternative explanations for abnormal DA responsiveness that do not rely on changes in the vasa vasorum.
Thus, mouse models of persistent DA patency may provide novel insights into general mechanisms of DA regulation that are independent of vasa vasorum effects.
Overall, our data show that gestational maturity has significant but opposite effects on NO and prostaglandin regulation of the mouse DA. eNOS is constitutively expressed in most vascular beds, but our results suggest that there may be different roles for eNOS-derived NO in the preterm and term DA. In addition, the impact of NOS inhibition does not seem to be as severe as inhibition of prostaglandin synthesis. Indeed, mice with targeted deletions of NOS isoforms do not have overt DA abnormalities (19, 25, 37) whereas mice with disrupted prostaglandin signaling die on the first day of life with persistent DA patency (24, 34, 41, 42) .
The availability of mice lacking all three NOS isoforms may provide additional insight if compensatory upregulation of alternate NOS isoforms occurs in the DA as it does in the myocardium (22). Resolution of the mechanisms that regulate the DA will enhance our understanding of fetal transition after birth and may help prevent inadvertent constriction of the fetal DA in response to maternal drugs that are given during pregnancy. Dams treated with combined L-NAME and indomethacin received a single dose of each drug, due to fetal and maternal toxicity. For each experiment, fetal DA status was determined four hours after the last drug dose. Open and hatched bars correspond to the degree of DA patency in relationship to the main pulmonary artery (e.g., open bar = 50% patency, dark hatched bar = 75%
patency, solid bar = 100% patency). Inter-group comparisons were made for treatment groups and between gestational age groups. *p<0.01 for day 16 treatments compared to d16 saline or indomethacin; ** p<0.001 for day 16 versus d19 (comparing similar drug treatment groups); † p<0.001 for day 19 treatments compared to d19 saline or L-NAME. There was no significant difference in the degree of DA patency between saline and indomethacin on day 16, or between saline and L-NAME on day 19. Blue staining indicates lacZ expression under control of the flk promoter. AO, aorta; DA, ductus arteriosus; MPA, main pulmonary artery. Arrow, thin walled vessels; arrowhead, small muscular vessels consistent with superficial vasa vasorum in the adventitia and aortico-pulmonary membrane around the DA.
